Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Allergan and Editas Medicine have established an ophthalmic-disease-related R&D alliance. Allergan will pay $90 million up front to access up to five early-stage CRISPR genome-editing programs at Editas. Included is Editas’s lead program for Leber congenital amaurosis, a rare, inherited retinal degenerative disease. Allergan will be responsible for developing and commercializing any resulting products. Editas could codevelop up to two.
This article has been sent to the following recipient: